NCI Puts Genentech Studies On Hold, Citing IP Disagreement

From The Cancer Letter, March 12, 2010:

NCI placed a hold on new studies of three Genentech cancer drugs, citing ongoing disagreement over intellectual property provisions of the standard cooperative research and development agreements used by the institute.

The hold on new studies was announced by the NCI Cancer Therapy Evaluation Program in an email to clinical investigators March 3. The hold affects Avastin (bevacizumab) and two new drug candidates, hedgehog pathway inhibitor GDC-0449 and Bcl-2 inhibitor ABT-263. All three drugs are sponsored by Genentech, a unit of Roche. ABT-263 is being co-developed by Genentech and Abbott Laboratories.

For the rest of the story, click on The Cancer Letter Archive at left to read the March 12, 2010 issue (subscription or day pass required).
_____
tags: NCI|  drug development